down arrow

Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE1000032C9
  • SHE: 002864
CNY
21.36
-0.07 (-0.33%)

Sep 22

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.

Why is Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd. ?

1
Poor long term growth as Net Sales has grown by an annual rate of 7.88% and Operating profit at -2.67% over the last 5 years
2
Negative results in Mar 26
  • ROCE(HY) Lowest at 5.15%
  • NET SALES(Q) Lowest at CNY 222.54 MM
  • NET PROFIT(Q) Fallen at -30.36%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -5.42% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.
-7.78%
-0.02
36.79%
China Shanghai Composite
3.23%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
7.88%
EBIT Growth (5y)
-2.67%
EBIT to Interest (avg)
29.16
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.58
Tax Ratio
18.53%
Dividend Payout Ratio
29.30%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.71%
ROE (avg)
9.45%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
31
Industry P/E
Price to Book Value
1.57
EV to EBIT
18.42
EV to EBITDA
13.90
EV to Capital Employed
2.55
EV to Sales
1.44
PEG Ratio
NA
Dividend Yield
0.18%
ROCE (Latest)
13.87%
ROE (Latest)
5.07%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
OPERATING CASH FLOW(Y)

Highest at CNY 176.92 MM

DIVIDEND PAYOUT RATIO(Y)

Highest at 65.83%

RAW MATERIAL COST(Y)

Fallen by -24.29% (YoY

CASH AND EQV(HY)

Highest at CNY 2,427.13 MM

DEBT-EQUITY RATIO (HY)

Lowest at -65.9 %

DIVIDEND PER SHARE(HY)

Highest at CNY 1.82

-23What is not working for the Company
ROCE(HY)

Lowest at 4.62%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.82 times

NET SALES(Q)

Lowest at CNY 200.04 MM

PRE-TAX PROFIT(Q)

Fallen at -27.27%

NET PROFIT(Q)

Fallen at -28.63%

Here's what is working for Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.

Operating Cash Flow
Highest at CNY 176.92 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Cash and Eqv
Highest at CNY 2,427.13 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -65.9 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Dividend per share
Highest at CNY 1.82
in the last five years
MOJO Watch
Company is distributing higher dividend from profits generated

DPS (CNY)

Dividend Payout Ratio
Highest at 65.83%
in the last five years
MOJO Watch
Company is distributing higher proportion of profits generated as dividend

DPR (%)

Raw Material Cost
Fallen by -24.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shaanxi Panlong Pharmaceutical Group Ltd. By Share Ltd.

Net Sales
At CNY 200.04 MM has Fallen at -38.22%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Net Sales
Lowest at CNY 200.04 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (CNY MM)

Pre-Tax Profit
Fallen at -27.27%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit
Fallen at -28.63%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

Debtors Turnover Ratio
Lowest at 1.82 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Footer loading